BeiGene further invests in ADCs with solid tumor partner DualityBio, a BioNTech collaborator
BeiGene is expanding its cancer arsenal with an antibody-drug conjugate deal, enlisting the same Shanghai biotech that teamed up with BioNTech in April.
The solid tumor partnership with DualityBio will help BeiGene broaden its early-stage presence in the ADC field. The space has grown with the success of AstraZeneca and Daiichi Sankyo’s breast cancer treatment Enhertu, Pfizer’s planned $43 billion acquisition of Seagen, and a series of industry collaborations looking to make the next big dent in oncology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.